Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial

Kenneth G. Saag*, Nicola Pannacciulli, Piet Geusens, Jonathan D. Adachi, Osvaldo D. Messina, Jorge Morales-Torres, Ronald Emkey, Peter W. Butler, Xiang Yin, Willem F. Lems

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Fingerprint

Dive into the research topics of 'Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial'. Together they form a unique fingerprint.

Keyphrases

INIS

Pharmacology, Toxicology and Pharmaceutical Science